FINNENCE ▪ THE WIRE FILE
THE WIRE · № 70741
SEC Filing■ Unclear/unknown
PEP filed 8-K on 2026-10-08
KINDSEC Filing
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES2
STORY SIZESTANDALONE
FIRST SEEN2026-10-08 00:00 UTC
LAST UPDATE2026-10-08 00:00 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
An 8-K with earnings results (item 2.02) signals a quarterly report, but no numbers are given so direction cannot be assessed.
Earnings 8-K filed but figures not provided
CATALYST TO WATCH
Actual earnings figures and guidance
MAIN RISK
Results could disappoint once numbers are known
FULL DISPATCH
PEP (CIK 0000077476) filed a 8-K on 2026-10-08. 8-K items: item 2.02 (results of operations (earnings)) item 9.01.
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
SUBJECTPepsiCo · PEP
AFFECTEDConsumer
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→INFERENCEfilings generate company commentary
New Phase 3 trial: J-LINX: Japan LINerixibat eXtension Study — GlaxoSmithKline2026-10-06 12:00 UTC
New Phase 3 trial: J-LINX: Japan LINerixibat eXtension Study — GlaxoSmithKline2026-10-06 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity — Novo Nordisk A/S2026-10-06 12:00 UTC
New Phase 3 trial: A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity — Novo Nordisk A/S2026-10-06 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: Phase 3 Evaluation of Sovateltide for the Treatment of Acute Traumatic Brain Injury — Pharmazz, Inc.2026-10-06 12:00 UTC
New Phase 3 trial: Phase 3 Evaluation of Sovateltide for the Treatment of Acute Traumatic Brain Injury — Pharmazz, Inc.2026-10-06 12:00 UTC
→INFERENCEfilings generate company commentary
Phase 3 results posted: A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery — Vascular Therapies, Inc.2026-10-06 12:00 UTC
Phase 3 results posted: A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery — Vascular Therapies, Inc.2026-10-06 12:00 UTC
→INFERENCEfilings generate company commentary
Phase 3 results posted: A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) — Janssen Research & Development, LLC2026-10-06 12:00 UTC
Phase 3 results posted: A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) — Janssen Research & Development, LLC2026-10-06 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne — Sagimet Biosciences Inc.2026-10-07 12:00 UTC
New Phase 3 trial: Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne — Sagimet Biosciences Inc.2026-10-07 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.